分子靶向治疗在急性髓系白血病中的研究进展
Progress of molecular targeted therapy in acute myeloid leukemia
蔡少芬 1孔繁聪 1李菲1
作者信息
- 1. 南昌大学第一附属医院血液病中心,江西省血液病临床医学研究中心(南昌,330006)
- 折叠
摘要
急性髓系白血病(acute myeloid leukemia,AML)是一种高度异质性的血液系统恶性肿瘤,常规治疗以细胞毒药物化疗为主,但总体疗效不理想,5年生存率不到30％.近年来随着对AML发病机制及基因突变认识的逐渐深入,一系列新型分子靶向药物相继问世.这些药物明显改善了 AML患者的预后,为AML患者提供更多的治疗选择.本文就分子靶向治疗在AML中的研究进展作一综述.
Abstract
Acute myeloid leukemia(AML)is a highly heterogeneous hematologic malignancy.The conven-tional treatment of AML is cytotoxic chemotherapy.However,the overall survival of AML is not ideal and the 5-year survival rate is less than 30％.Recently,a series of novel molecular targeted drugs have been developed.These drugs have significantly improved the prognosis of patients with AML and provided more treatment op-tions.This article reviews the progress of molecular targeted therapy in AML.
关键词
急性髓系白血病/靶向治疗/研究进展Key words
acute myeloid leukemia/targeted therapy/progress引用本文复制引用
基金项目
江西省科技创新基地项目(20212BCG74001)
江西省科技创新基地项目(20211ZDG02006)
江西省自然科学基金(20203BBGL7319)
江西省卫健委项目(202210438)
出版年
2024
NETL
NSTL
万方数据